Lv1
44 积分 2024-03-22 加入
Synthetic cytokine circuits that drive T cells into immune-excluded tumors
23天前
已完结
Antibody targeted delivery of lipid nanoparticles for RNA therapeutics to immune cells
28天前
已完结
A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia
3个月前
已完结
A multicentre double‐blind, double‐dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients
3个月前
已完结
Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy
3个月前
已完结
Dose tapering to withdrawal stage and long‐term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open‐label extension study
3个月前
已完结
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study
3个月前
已完结
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
3个月前
已完结
An mRNA vaccine encoding proteasome-targeted antigen enhances CD8+ T cell immunity
6个月前
已完结
Targeted MYC2 stabilization confers citrus Huanglongbing resistance
7个月前
已完结
皖公网安备34019202002308
